Elixin Pharma

Elixin Pharma is a scientific and regulatory consulting firm founded in 1999, specializing in Chemistry, Manufacturing, and Controls (CMC) for novel pharmaceutical technologies. The company provides deep expertise in the development and regulatory submission of oligonucleotide-based therapeutics, including antisense, siRNA, miRNA, and aptamers. Led by President Susan Srivatsa, Elixin Pharma assists both emerging and established biotech companies with CMC strategy, technical writing, and defense of regulatory applications across global markets including the US, EU, and Asia. The firm is recognized for its contributions to the development of complex dosage forms and its involvement in high-profile RNA therapeutic projects, including the first oligonucleotide drug approvals in the US and Europe.